Devoted to the life sciences with persistence, Kexing Biopharm has focused on the innovation and industrialization of biopharmaceuticals,and established a relatively complete system of pharmaceutical R&D, covering pharmaceutical innovation capabilities from pharmaceutical discovery, pharmaceutical research, preclinical research and clinical research to industrialized production.
At present, we have obtained 45 patents, An R&D team of more than 200 personnel (53.85% of them possess a master's degree or above).
Product Pipeline
Preclinical study
Clinical I Study
Clinical II Study
Clinical III Study
Antiviral
Human α1b Interferon inhalation solution
Antitumr
Long-acting recombinant human G-CSF
Antiviral
SHEN26 COVID-19 oral capsules
Antitumor
Bispecific antibody for ocular fundus
Monoclonal antibody for cancer cachexia
Trispecific antibody for solid tumor
Trispecific antibody for Colorectal Cancer
Autoimmune Disorders
Bispecific antibody for Atopic Dermatitis
Monoclonal antibody for Systemic Lupus Erythematosus
Monoclonal antibody for Ulcerative Coliti
Bispecific antibody for Ulcerative Colitis
Bispecific antibody for Systemic Lupus Erythematosus
Multiple Autoimmune Diseases